Moderate To Severe Copd clinical trials

Explore recruiting moderate to severe copd clinical trials.

Recruiting moderate to severe copd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Copd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Czechia, Germany, Poland, Hungary, Spain, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) (AERIFY-1)

Romania, Slovakia, Bulgaria, Italy, Czechia, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)

Poland, Germany, Italy, France, Romania, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)

Czechia, Denmark, Bulgaria, Netherlands, Belgium, Finland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)

Greece, Denmark, Netherlands, Poland, Belgium, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Spain, Germany, Poland, Czechia, Greece, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Copd trials by city

Moderate To Severe Copd in Toronto Moderate To Severe Copd in Vancouver Moderate To Severe Copd in Montreal Moderate To Severe Copd in Calgary Moderate To Severe Copd in Edmonton Moderate To Severe Copd in Ottawa Moderate To Severe Copd in Winnipeg Moderate To Severe Copd in Quebec City Moderate To Severe Copd in Hamilton Moderate To Severe Copd in Kitchener Moderate To Severe Copd in London Moderate To Severe Copd in Halifax Moderate To Severe Copd in New York Moderate To Severe Copd in Los Angeles Moderate To Severe Copd in Chicago Moderate To Severe Copd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease